This course is part of the Strategies for Effective Pain Management in Clinical Practice curriculum.
Pain management title

This course is part of the Strategies for Effective Pain Management in Clinical Practice curriculum.


1.00 CME Credit

Part 2: Reducing Risks with Opioid UseStrategies for Effective Pain Management in Clinical PracticeAn Interactive Video Experience: This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Upon completing the activity, you will be prompted to return to

Reducing Risks with Opioid Use is part 2 of the 3-part curriculum, Strategies for Effective Pain Management in Clinical Practice, which examines the full spectrum of pain management options available to clinicians, including the safe and effective use of opioids.

In Part 2, you will learn about different opioids available for pain management and best practices for reducing risk associated with opioid use. You will also learn how to recognize signs of opioid use disorder and distinguish it from tolerance and physical dependence, and how to recognize and treat opioid overdose in your patients.

Information on the entire curriculum, including learning objectives, is located here.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).


Learning Objectives

  • Differentiate among tolerance, physical dependence, and addiction
  • Recognize best practices to reduce the risks associated with prescription of opioid analgesics, as well as safe storage and disposal
  • Distinguish signs of opioid use disorder as well as signs of overdose and its treatment


Charles E. Argoff, MD, FABPM

Vice Chair
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, NY

Learn More

Oscar A. de Leon-Casasola, MD

Professor of Anesthesiology and Medicine 
Senior Vice-Chair
The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo 
Chief, Pain Medicine and Professor of Oncology 
Roswell Park Cancer Institute
Buffalo, NY

Learn More

Katherine E. Galluzzi, DO, CMD, FACOFP

Professor and Chair
Department of Geriatric and Palliative Medicine
Director, Comprehensive Care
Philadelphia College of Osteopathic Medicine
Philadelphia, PA

Learn More


The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Charles E. Argoff, MD, FABPM: Speaker’s bureau: AbbVie, Amgen, Averitas Pharma, Biohaven, Grunenthal, Impel, Kowa Pharmaceuticals America, Lilly, Lundbeck, Neumentum, Nevro, Redhill Biopharma, and Teva Pharmaceuticals. Advisory Board: AbbVie, Amgen, Averitas Pharma, BioDelivery Sciences International, Clexio Biosciences, EnZen Therapeutics, Kowa, Lundbeck, Nevro, Regeneron, SK Life Sciences, Tremeau Pharmaceuticals, Teva, Tris, Vertex and Xgene Pharma. Consulting: EnZen Therapeutics, Neumentum, Opioid PMR Consortium, PainScripts, and Xgene Pharmaceutical. Researcher: AbbVie, Allergan, Amgen, Lilly, Lundbeck, and Teva. Royalties or patent beneficiaries: Elsevier. Stock Holder: Pfizer and Trevena. Other services provided: Collegium.

Oscar A. de Leon-Casasola, MD: Advisory board: Esteve Pharmaceuticals. Advisory board: Heron Therapeutics and Tremeau Pharmaceuticals. Consultant: Kowa Pharmaceuticals.

Katherine E. Galluzzi, DO, CMD, FACOFP: No relevant financial relationships have been disclosed.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME Information

AMA PRA Category 1 Credits

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This activity is approved for 1.07 contact hours of continuing education, which includes 0.71 hours of pharmacology.

MOC Credit Information

Successful completion of this CME activity (“Strategies for Effective Pain Management in Clinical Practice”), which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge & Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Other Boards:

Through the American Board of Medical Specialties (“ABMS”) ongoing  commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory (, Strategies for Effective Pain Management in Clinical Practice has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity:
Allergy and Immunology
Colon and Rectal Surgery
Family Medicine
Physical Medicine and Rehabilitation
Plastic Surgery
Preventive Medicine
Psychiatry and Neurology
Thoracic Surgery

This MOC/CME is self-reported to the Boards listed above.

State Licensure Requirements

This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation.

Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, which may also satisfy the medical ethics and/or professional responsibility.

Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.

Supporters and Partners

Commercial Supporter

Opioid Analgesic REMS Program Companies

Education Partner

Miller Medical Communications, LLC

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email or call (877) 477-4633.

Part 2: Reducing Risks with Opioid Use